AstraZeneca sells off third drug in five days
October 7, 2016Medical Communications AstraZeneca, Cilag GmbH, Johnson & Johnson, Rhinocort Aqua
AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside …
ICU Medical to acquire Pfizer’s global infusion therapy business in $1 billion deal
October 6, 2016Medical Communications Hospira, ICU medical, Pfizer, acquisition, infusion
The $1 billion deal that will take place as ICU Medical Inc. take over Pfizer’s Hospira Infusion Systems will be …
“Incorrect classification” of EpiPen leads to $1 billion bill for US government
October 6, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cost, Heather Bresch, Misclassification, Mylan, Price hike, classification, epipen, price, scandal
Mylan’s EpiPen woes show no sign of abating after CMS (Centers for Medicare and Medicaid Services) released figures that show …
Teva to sell Allergan’s UK & Ireland generics business for $770m
October 6, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva
Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.
Alnylam’s shares plunge by 42% after deaths in clinical trials
October 6, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran
Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …
Novartis axes 175 jobs globally in operations reshuffle
October 5, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Novartis has announced it is to shut down parts of its research operations in Switzerland and China and cutting 175 …
Merck’s Keytruda suffers rejection at hands of NICE
October 5, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda
NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …
AZ “disappointment” at heart drug failure
October 5, 2016Research and Development AZ, AstraZeneca, trial failure
AstraZeneca has expressed its disappointment that its heart drug Brilinta (ticagrelor) failed to meet its primary endpoint in a recent …
FDA warns that certain hepatitis C drugs can have serious side-effects
October 5, 2016Medical Communications, Research and Development FDA, hepatitis B, hepatitis C
The FDA has issued a warning to patients who are currently taking drugs to treat hepatitis C that they may …
Mylan’s promised half-price EpiPen not available until year’s end
October 5, 2016Research and Development, Sales and Marketing Mylan, epipen
Consumers may have to wait until the end of the year for the half-price EpiPen, months after Mylan originally promised …
Roche granted breakthrough therapy designation by FDA
October 5, 2016Research and Development Actemra, FDA, Giant Cell arteritis, Roche, breakthrough therapy
Roche has announced that the FDA has granted its Actembra drug breakthrough therapy designation for giant cell arteritis. The breakthrough …
Patients’ insulin pumps are revealed to be hackable by J&J
October 4, 2016Research and Development, Sales and Marketing FDA, Hackers, Johnson & Johnson, diabetes, insulin
Johnson & Johnson have begun warning patients that their insulin pumps, that patients attach to their bodies and are controlled …
Roche’s Alecensa receives second FDA Breakthrough Therapy Designation
October 4, 2016Manufacturing and Production ALK+, Alecensa, FDA, Roche, alk, crizotinib
Alecensa has been designated as a breakthrough therapy, which will speed up the process towards FDA approval, should clinical trials …
AstraZeneca’s wins major drug approval by NICE
October 4, 2016Manufacturing and Production AstraZeneca, Cancer Drug Fund, NHS, Tagrisso
AstraZeneca’s Tagrisso (osimertinib) has successfully received endorsement of Britain’s Cancer Drugs Fund that has a reserve of £340 million to …
Sanofi’s dengue vaccine scores 11th worldwide approval in Singapore
October 4, 2016Sales and Marketing Sanofi, dengue, drug approval
Sanofi Pasteur, the vaccines unit of the wider French firm, has announced that its dengue vaccine Dengvaxia has secured market …
NICE and the CDF: Are they still up to scratch?
October 4, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE
Originally published in the October issue of Pharmafocus, Matt Fellows explores medical and pharmaceutical opinion of the divisive institute to …
$600m acquisition bolsters Celgene’s blood cancer portfolio
October 3, 2016Manufacturing and Production, Research and Development Celgene, EngMab, acquisition, lymphoma, multiple myeloma
Celgene has shelled out $600m for Swiss biotech EngMab in an effort to reinforce its blood cancer portfolio with a …
Merrimack Pharmaceuticals’ CEO resigns and workforce cut by nearly a quarter
October 3, 2016Sales and Marketing Gary Crocker, Merrimack Pharmaceuticals, Robert Mulroy
Merrimack Pharmaceuticals announced that they would cut away 22% of their workforce and their CEO, Robert Mulroy, would leave immediately …
J&J’s IL-23 drug guselkumab outstrips the competition in Phase III trial
October 3, 2016Research and Development, Sales and Marketing AbbVie, Humira, Johnson & Johnson, guselkumab
Johnson & Johnson’s IL-23 drug guselkumab proved to be more effective at clearing moderate to severe cases of the plaque …
Regeneron’s Eylea fails combination study endpoint
October 3, 2016Research and Development, Sales and Marketing Eylea, Regeneron
Regeneron has announced that its eye drug Eylea (aflibercept) failed its primary endpoint in a mid-stage trial investigating its effectiveness …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
